OMERS ADMINISTRATION Corp Purchases 1,088,354 Shares of Gilead Sciences, Inc. $GILD

OMERS ADMINISTRATION Corp increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1,456.8% during the first quarter, HoldingsChannel reports. The institutional investor owned 1,163,062 shares of the biopharmaceutical company’s stock after acquiring an additional 1,088,354 shares during the quarter. Gilead Sciences comprises 1.0% of OMERS ADMINISTRATION Corp’s investment portfolio, making the stock its 23rd biggest position. OMERS ADMINISTRATION Corp’s holdings in Gilead Sciences were worth $162,096,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. Strategic Investment Solutions Inc. IL bought a new position in Gilead Sciences in the 4th quarter worth about $25,000. Vermillion & White Wealth Management Group LLC raised its holdings in shares of Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 85 shares in the last quarter. Quattro Advisors LLC bought a new stake in shares of Gilead Sciences during the 4th quarter valued at about $26,000. Wealth Preservation Advisors LLC boosted its position in shares of Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 81 shares during the last quarter. Finally, Wilkerson Advisory Group LLC grew its holdings in shares of Gilead Sciences by 54.2% during the first quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 78 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Weiss Ratings cut shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, May 28th. Morgan Stanley dropped their target price on shares of Gilead Sciences from $168.00 to $166.00 and set an “overweight” rating for the company in a research report on Wednesday, July 8th. Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a research note on Wednesday, May 20th. Truist Financial decreased their price target on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Finally, Royal Bank Of Canada dropped their price objective on shares of Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a report on Tuesday, July 7th. Twenty-five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $158.33.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the transaction, the chief financial officer owned 171,646 shares in the company, valued at approximately $21,524,408.40. This trade represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $126.29, for a total transaction of $1,894,350.00. Following the completion of the transaction, the chief executive officer directly owned 607,133 shares in the company, valued at approximately $76,674,826.57. The trade was a 2.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 77,000 shares of company stock valued at $9,978,740 in the last ninety days. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $129.31 on Friday. The company has a 50-day simple moving average of $129.55 and a two-hundred day simple moving average of $135.50. Gilead Sciences, Inc. has a 12-month low of $108.46 and a 12-month high of $157.29. The firm has a market cap of $160.55 billion, a price-to-earnings ratio of 17.62 and a beta of 0.32. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter in the previous year, the business earned $1.81 earnings per share. The company’s quarterly revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post -0.77 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend was Monday, June 15th. Gilead Sciences’s payout ratio is 44.69%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.